Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

This study has been completed.

Study NCT00077428 Information provided by National Cancer Institute (NCI)

First Received: February 10, 2004 Last Updated: January 27, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Publications:

Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the eastern cooperative oncology group (E1303). Cancer. 2011 Jan 18; [Epub ahead of print]

Argiris A, Goldwasser MA, Burtness B, et al.: A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group. [Abstract] J Clin Oncol 24 (Suppl 18): A-5573, 2006.